Correlation of focal neuroendocrine differentiation in prostate cancer with the parameters of predictive value

被引:0
作者
Mijovic, Milica [1 ]
Corac, Aleksandar [2 ]
Smiljic, Sonja [3 ]
Savic, Sladjana [4 ]
Mandic, Predrag [5 ]
Vitkovic, Leonida [4 ]
Lestarevic, Snezana [4 ]
Hudomal, Snezana Janicijevic [6 ]
机构
[1] Univ Pristina Kosovska Mitrovica, Fac Med, Inst Pathol, Ann Dinana Bb, Kosovska Mitrovica 38220, Serbia
[2] Univ Pristina Kosovska Mitrovica, Dept Prevent Med, Kosovska Mitrovica, Serbia
[3] Univ Pristina Kosovska Mitrovica, Inst Physiol, Kosovska Mitrovica, Serbia
[4] Univ Pristina Kosovska Mitrovica, Inst Histol, Kosovska Mitrovica, Serbia
[5] Univ Pristina Kosovska Mitrovica, Inst Anat, Kosovska Mitrovica, Serbia
[6] Univ Pristina Kosovska Mitrovica, Inst Pharmacol, Kosovska Mitrovica, Serbia
关键词
prostatic neoplasms; neuroendocrinology; prostate-specific antigen; risk factors; neoplasm staging; prognosis; PROGNOSTIC-SIGNIFICANCE; CHROMOGRANIN-A; NEEDLE-BIOPSY; CARCINOMA; ADENOCARCINOMA; VOLUME; CELLS; PSA;
D O I
10.2298/VSP170930019M
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim. Neuroendocrine (NE) cells are one of the epithelial populations in the prostate. It is well-known that the focal neuroendocrine differentiation (FNED) in prostate cancer (PC) is an aggressive subtype that most commonly evolves from preexisting PC which does not respond to hormone therapy (androgen independed PC). The incidence and clinical importance of FNED in PC is not clearly understood because of conflicting results in the studies, and evaluation of FNED is not routinely performed in clinical practice. The aim of the present study is to determine the importance of FNED presence in the examined prostate changes with special reference to the relationship of FNED degree in PC with some parameters of predictive value [Gleason score, preoperative serum total prostata specific antigen (PSA) value, tumor volume and tumor stage]. Methods. The study included the biopsy material from 100 untreated consecutive prostate pathological changes: 70 PC, 20 prostatic intraepithelial neoplasia (PIN) and 10 benign prostatic hyperplasia (BPH). The patients with PIN and BPH were the control groups. A block containing part of the main bulk of pathological change was chosen as representative based on hematoxylin-eosin appearance, and a section of this block was immunohistochemically stained for the tissue PSA (to mark prostatic secretory cells) and chromogranin A, serotonin and synaptophysin (to mark NE cells). Results. We found a very pronounced degree of FNED differentiation in 16 (22.9%) PC. Ten (62.5%) of them had Gleason score >= 7, the average serum PSA level was 32.62 +/- 30.80 ng/mL, average tumor volume was 43.18 +/- 31.45 mL and 6 (37.5%) of this PC were detected in D clinical stage with distant hematogenous metastases. The FNED is negatively correlated with the serum PSA level, Gleason score and clinical stage positively correlated with the tumor volume, but without statistically significant differences. Conclusion. The FNED has no significant role in the prognosis of PC.
引用
收藏
页码:1115 / 1126
页数:12
相关论文
共 51 条
  • [1] Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO
  • [2] 2-S
  • [3] THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER
    ABRAHAMSSON, PA
    FALKMER, S
    FALT, K
    GRIMELIUS, L
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) : 373 - 380
  • [4] Abrahamsson PA, 1998, PROSTATE, P37
  • [5] Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens
    Amin, M
    Boccon-Gibod, L
    Egevad, L
    Epstein, JI
    Humphrey, PA
    Mikuz, G
    Newling, D
    Nilsson, S
    Sakr, W
    Srigley, JR
    Wheeler, TM
    Montironi, R
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2005, 39 : 20 - 33
  • [6] Neuroendocrine cells in prostate cancer
    Amorino, GP
    Parsons, SJ
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2004, 14 (04): : 287 - 300
  • [7] Ather M Hammad, 2004, BMC Urol, V4, P14
  • [8] Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer
    Ather M.H.
    Abbas F.
    Faruqui N.
    Israr M.
    Pervez S.
    [J]. BMC Urology, 8 (1)
  • [9] Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
    Beltran, Himisha
    Rickman, David S.
    Park, Kyung
    Chae, Sung Suk
    Sboner, Andrea
    MacDonald, Theresa Y.
    Wang, Yuwei
    Sheikh, Karen L.
    Terry, Stephane
    Tagawa, Scott T.
    Dhir, Rajiv
    Nelson, Joel B.
    de la Taille, Alexandre
    Allory, Yves
    Gerstein, Mark B.
    Perner, Sven
    Pienta, Kenneth J.
    Chinnaiyan, Arul M.
    Wang, Yuzhuo
    Collins, Colin C.
    Gleave, Martin E.
    Demichelis, Francesca
    Nanus, David M.
    Rubin, Mark A.
    [J]. CANCER DISCOVERY, 2011, 1 (06) : 487 - 495
  • [10] Models of neuroendocrine prostate cancer
    Berman-Booty, Lisa D.
    Knudsen, Karen E.
    [J]. ENDOCRINE-RELATED CANCER, 2015, 22 (01) : R33 - R49